Adjuvant radiotherapy in the treatment of invasive intraductal papillary mucinous neoplasm of the pancreas: An analysis of the surveillance, epidemiology, and end results registry

Mathias Worni, Igor Akushevich, Beat Gloor, John Scarborough, Junzo P. Chino, Danny O. Jacobs, Stephen M. Hahn, Bryan M. Clary, Ricardo Pietrobon, Anand Shah

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background. Management and outcomes of patients with invasive intraductal papillary mucinous neoplasm (IPMN) of the pancreas are not well established. We investigated whether adjuvant radiotherapy (RT) improved cancer-specific survival (CSS) and overall survival (OS) among patients undergoing surgical resection for invasive IPMN. Methods. The Surveillance, Epidemiology, and End Results (SEER) registry was used in this retrospective cohort study. All adult patients with resection of invasive IPMN from 1988 to 2007 were included. CSS and OS were analyzed using Kaplan-Meier curves. Unadjusted and propensity-score-adjusted Cox proportional-hazards modeling were used for subgroup analyses. Results. 972 patients were included. Adjuvant RT was administered to 31.8% (n = 309) of patients. There was no difference in overall median CSS or OS in patients who received adjuvant RT (5-year CSS: 26.5 months; 5-year OS: 23.5 months) versus those who did not (CSS: 28.5 months, P = 0.17; OS: 23.5 months, P = 0.23). Univariate predictors of survival were lymph node (LN) involvement, T4-classified tumors, and poorly differentiated tumor grade (all P < 0.05). In the propensity-score-adjusted analysis, adjuvant RT was associated with improved 5-year CSS [hazard ratio (HR): 0.67, P = 0.004] and 5-year OS (HR: 0.73, P = 0.014) among all patients with LN involvement, though further analysis by T-classification demonstrated no survival differences among patients with T1/T2 disease; patients with T3/T4-classified tumors had improved CSS (HR: 0.71, P = 0.022) but no difference in OS (HR: 0.76, P = 0.06). Conclusion. On propensity-score-adjusted analysis, adjuvant RT was associated with improved survival in selected subsets of patients with invasive IPMN, particularly those with T3/T4 tumors and LN involvement.

Original languageEnglish (US)
Pages (from-to)1316-1323
Number of pages8
JournalAnnals of Surgical Oncology
Volume19
Issue number4
DOIs
StatePublished - Apr 2012
Externally publishedYes

Fingerprint

Adjuvant Radiotherapy
Pancreatic Neoplasms
Registries
Epidemiology
Survival
Neoplasms
Therapeutics
Propensity Score
Lymph Nodes

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Adjuvant radiotherapy in the treatment of invasive intraductal papillary mucinous neoplasm of the pancreas : An analysis of the surveillance, epidemiology, and end results registry. / Worni, Mathias; Akushevich, Igor; Gloor, Beat; Scarborough, John; Chino, Junzo P.; Jacobs, Danny O.; Hahn, Stephen M.; Clary, Bryan M.; Pietrobon, Ricardo; Shah, Anand.

In: Annals of Surgical Oncology, Vol. 19, No. 4, 04.2012, p. 1316-1323.

Research output: Contribution to journalArticle

Worni, Mathias ; Akushevich, Igor ; Gloor, Beat ; Scarborough, John ; Chino, Junzo P. ; Jacobs, Danny O. ; Hahn, Stephen M. ; Clary, Bryan M. ; Pietrobon, Ricardo ; Shah, Anand. / Adjuvant radiotherapy in the treatment of invasive intraductal papillary mucinous neoplasm of the pancreas : An analysis of the surveillance, epidemiology, and end results registry. In: Annals of Surgical Oncology. 2012 ; Vol. 19, No. 4. pp. 1316-1323.
@article{69778c9936cd44579fab2a3505e22268,
title = "Adjuvant radiotherapy in the treatment of invasive intraductal papillary mucinous neoplasm of the pancreas: An analysis of the surveillance, epidemiology, and end results registry",
abstract = "Background. Management and outcomes of patients with invasive intraductal papillary mucinous neoplasm (IPMN) of the pancreas are not well established. We investigated whether adjuvant radiotherapy (RT) improved cancer-specific survival (CSS) and overall survival (OS) among patients undergoing surgical resection for invasive IPMN. Methods. The Surveillance, Epidemiology, and End Results (SEER) registry was used in this retrospective cohort study. All adult patients with resection of invasive IPMN from 1988 to 2007 were included. CSS and OS were analyzed using Kaplan-Meier curves. Unadjusted and propensity-score-adjusted Cox proportional-hazards modeling were used for subgroup analyses. Results. 972 patients were included. Adjuvant RT was administered to 31.8{\%} (n = 309) of patients. There was no difference in overall median CSS or OS in patients who received adjuvant RT (5-year CSS: 26.5 months; 5-year OS: 23.5 months) versus those who did not (CSS: 28.5 months, P = 0.17; OS: 23.5 months, P = 0.23). Univariate predictors of survival were lymph node (LN) involvement, T4-classified tumors, and poorly differentiated tumor grade (all P < 0.05). In the propensity-score-adjusted analysis, adjuvant RT was associated with improved 5-year CSS [hazard ratio (HR): 0.67, P = 0.004] and 5-year OS (HR: 0.73, P = 0.014) among all patients with LN involvement, though further analysis by T-classification demonstrated no survival differences among patients with T1/T2 disease; patients with T3/T4-classified tumors had improved CSS (HR: 0.71, P = 0.022) but no difference in OS (HR: 0.76, P = 0.06). Conclusion. On propensity-score-adjusted analysis, adjuvant RT was associated with improved survival in selected subsets of patients with invasive IPMN, particularly those with T3/T4 tumors and LN involvement.",
author = "Mathias Worni and Igor Akushevich and Beat Gloor and John Scarborough and Chino, {Junzo P.} and Jacobs, {Danny O.} and Hahn, {Stephen M.} and Clary, {Bryan M.} and Ricardo Pietrobon and Anand Shah",
year = "2012",
month = "4",
doi = "10.1245/s10434-011-2088-2",
language = "English (US)",
volume = "19",
pages = "1316--1323",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Adjuvant radiotherapy in the treatment of invasive intraductal papillary mucinous neoplasm of the pancreas

T2 - An analysis of the surveillance, epidemiology, and end results registry

AU - Worni, Mathias

AU - Akushevich, Igor

AU - Gloor, Beat

AU - Scarborough, John

AU - Chino, Junzo P.

AU - Jacobs, Danny O.

AU - Hahn, Stephen M.

AU - Clary, Bryan M.

AU - Pietrobon, Ricardo

AU - Shah, Anand

PY - 2012/4

Y1 - 2012/4

N2 - Background. Management and outcomes of patients with invasive intraductal papillary mucinous neoplasm (IPMN) of the pancreas are not well established. We investigated whether adjuvant radiotherapy (RT) improved cancer-specific survival (CSS) and overall survival (OS) among patients undergoing surgical resection for invasive IPMN. Methods. The Surveillance, Epidemiology, and End Results (SEER) registry was used in this retrospective cohort study. All adult patients with resection of invasive IPMN from 1988 to 2007 were included. CSS and OS were analyzed using Kaplan-Meier curves. Unadjusted and propensity-score-adjusted Cox proportional-hazards modeling were used for subgroup analyses. Results. 972 patients were included. Adjuvant RT was administered to 31.8% (n = 309) of patients. There was no difference in overall median CSS or OS in patients who received adjuvant RT (5-year CSS: 26.5 months; 5-year OS: 23.5 months) versus those who did not (CSS: 28.5 months, P = 0.17; OS: 23.5 months, P = 0.23). Univariate predictors of survival were lymph node (LN) involvement, T4-classified tumors, and poorly differentiated tumor grade (all P < 0.05). In the propensity-score-adjusted analysis, adjuvant RT was associated with improved 5-year CSS [hazard ratio (HR): 0.67, P = 0.004] and 5-year OS (HR: 0.73, P = 0.014) among all patients with LN involvement, though further analysis by T-classification demonstrated no survival differences among patients with T1/T2 disease; patients with T3/T4-classified tumors had improved CSS (HR: 0.71, P = 0.022) but no difference in OS (HR: 0.76, P = 0.06). Conclusion. On propensity-score-adjusted analysis, adjuvant RT was associated with improved survival in selected subsets of patients with invasive IPMN, particularly those with T3/T4 tumors and LN involvement.

AB - Background. Management and outcomes of patients with invasive intraductal papillary mucinous neoplasm (IPMN) of the pancreas are not well established. We investigated whether adjuvant radiotherapy (RT) improved cancer-specific survival (CSS) and overall survival (OS) among patients undergoing surgical resection for invasive IPMN. Methods. The Surveillance, Epidemiology, and End Results (SEER) registry was used in this retrospective cohort study. All adult patients with resection of invasive IPMN from 1988 to 2007 were included. CSS and OS were analyzed using Kaplan-Meier curves. Unadjusted and propensity-score-adjusted Cox proportional-hazards modeling were used for subgroup analyses. Results. 972 patients were included. Adjuvant RT was administered to 31.8% (n = 309) of patients. There was no difference in overall median CSS or OS in patients who received adjuvant RT (5-year CSS: 26.5 months; 5-year OS: 23.5 months) versus those who did not (CSS: 28.5 months, P = 0.17; OS: 23.5 months, P = 0.23). Univariate predictors of survival were lymph node (LN) involvement, T4-classified tumors, and poorly differentiated tumor grade (all P < 0.05). In the propensity-score-adjusted analysis, adjuvant RT was associated with improved 5-year CSS [hazard ratio (HR): 0.67, P = 0.004] and 5-year OS (HR: 0.73, P = 0.014) among all patients with LN involvement, though further analysis by T-classification demonstrated no survival differences among patients with T1/T2 disease; patients with T3/T4-classified tumors had improved CSS (HR: 0.71, P = 0.022) but no difference in OS (HR: 0.76, P = 0.06). Conclusion. On propensity-score-adjusted analysis, adjuvant RT was associated with improved survival in selected subsets of patients with invasive IPMN, particularly those with T3/T4 tumors and LN involvement.

UR - http://www.scopus.com/inward/record.url?scp=84862488011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862488011&partnerID=8YFLogxK

U2 - 10.1245/s10434-011-2088-2

DO - 10.1245/s10434-011-2088-2

M3 - Article

C2 - 22002799

AN - SCOPUS:84862488011

VL - 19

SP - 1316

EP - 1323

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 4

ER -